A once-weekly insulin to treat patients with adult diabetes has been approved in South Korea.

On December 23, the Ministry of Food and Drug Safety has approved Novo Nordisk's 'Awiqli Pre-Filled Pen 700 Units/mL (insulin icodec, recombinant).'

This drug is a once-weekly subcutaneous injection of insulin, providing a more convenient treatment option than the daily injections of conventional insulin.

Patients with type 1 diabetes must use Awiqli in combination with bolus insulin to meet their insulin requirements during meals. For type 2 diabetes, Awiqli can be administered as a monotherapy or in combination with oral antidiabetic agents, GLP-1 receptor agonists, and bolus ins